TargetBeta
CD276
CD276 molecule · also B7-H3, B7H3, B7RP-2 · CD molecules
13 programs in company-led studies act on CD276, from 13 companies: 7 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (8 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
Conditions their studies are in
- Small Cell Lung Carcinoma, 5 programs
- Carcinoma, Non-Small-Cell Lung, 3 programs
- Esophageal Squamous Cell Carcinoma, 3 programs
- Neoplasms, 3 programs
- Lung Neoplasms, 2 programs
- Prostatic Neoplasms, 2 programs
- Carcinoma, Hepatocellular, 1 program
- Colorectal Neoplasms, 1 program
- Diffuse Intrinsic Pontine Glioma, 1 program
- Fallopian Tube Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 30, 2026risvutatug rezetecan · Hansoh Pharmaceutical Group · phase 3 · NCT06699576
- Dec 30, 2026Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101 · TJ Biopharma · phase 3 · NCT07181473
- Jan 2027tambotatug pelitecan · MediLink Therapeutics (Suzhou) · phase 3 · NCT07208773
- Apr 30, 2027ifinatamab deruxtecan · Merck · phase 3 · NCT04145622
- May 2027Anti-B7-H3 Antibody-drug Conjugate MHB088C · Minghui Pharmaceutical · phase 3 · NCT06954246
- Jul 30, 2027Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034 · IDEAYA Biosciences · phase 1 · NCT07503808
- Dec 2027Elfetabart Drozuntecan · BioNTech · phase 3 · NCT05914116
- Dec 2027Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01 · Radiopharm Theranostics · phase 2 · NCT07189871
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.